Th is cohort study looks at the eff ectiveness of stem cell therapy (SCT) compared with supportive medical treatment (SMT) on health-related quality of life in patients with chronic liver disease (CLD) [1]. Studies such as this represent a valuable scientifi c approach, especially in the revolutionary fi eld of stem cell clinical applications [2][3][4]. Despite the limited available resources and diffi culty in carrying out such studies, especially in rural areas, the authors were able to demonstrate a clear and vivid association with better outcomes in patients enrolled in the SCT group compared with the SMT group.
Abstract
The work presented in this study focuses on evaluating health-related quality of life using the International Short Form 36-Item Health Survey in chronic liver disease patients in Cairo, Egypt, who received either stem cell therapy (SCT) or supportive medical treatment (SMT). Long-term follow-up results for patients who underwent therapy compared with healthy individuals showed that patients who underwent SCT showed marked improvements on all domains of the evaluation, much lower mortality rates, and complete absence of malignancy, compared with patients enrolled in SMT. The authors clearly showed a signifi cant advantage of SCT in chronic liver disease patients compared with SMT. shown by SMT patients after therapy. Additionally, there was a signifi cant distinction in mortality rates between SCT and SMT groups of 6% and 38%, respectively. More interestingly, the lack of malignancy in patients from the SCT group is of profound medical signifi cance [8] for a large population of patients suff ering from CLD in a country such as Egypt [9] .
However, it is important to highlight a few drawbacks in the study that may be of value to authors in future studies. Some of the data presented in this study are in agreement with published literature, while other data are not. Th is could most probably be due to variations in patients' profi les and cultural factors, or to diff erences in executing the study. Regardless of the reason for this disagreement, the authors should have presented a detailed discussion reasoning out their views on agreements and disagreements between their results and previously published reports. Additionally, we think that the literature review section was not fully covered and included a relatively low number of references. Only about one-half of the references cited in the paper were less than 5 years old. Th is could be either due to the lack of new references in this fi eld or due to the hastiness of authors to deeply investigate the literature. In either case, the authors should have made more eff ort to fully cover the rationalization in the fi eld of investigation. Moreover, the authors tend to emphasize that their study's outcomes are a refl ection of the patients' own perspective that found the overall experience of stem cell therapy a positive one, when other scientifi cally-based explanations are clearly possible and more reasonable in favoring stem cell therapy.
Collectively, the intensity and magnitude of the work performed in this report clearly manifests prominence in using advanced stem cell therapies for treating CLD. Th is is especially true in a country such as Egypt, which has the highest prevalence of hepatitis C virus infections in the world [10] , with a uniquely high risk profi le in these patients to develop hepatocellular carcinoma [11] following CLD. A more focused future study on stem cell therapy in hepatitis C virus-positive patients (that have signifi cantly higher rates of developing hepatocellular carcinoma), and its correlation to reducing their tendency to develop of the malignancy, will be of tremendous importance to this very intriguing fi eld of investigation.
Abbreviations CLD, chronic liver disease; SCT, stem cell therapy; SF-36 v2, International Short Form 36-Item Health Survey; SMT, supportive medical treatment.
